HUTCHMED's Fruquintinib Close to EU Approval
Chu Wong Pharmaceutical (00013.HK): Takeda receives positive feedback from the European Medicines Agency's Human Medicines Committee (CHMP) to support fruquintinib (fruquintinib) for the treatment of metastatic colorectal cancer
On April 26, Gelonghui Pharmaceutical (00013.HK) announced that its partner Takeda (TSE: 4502/ NYSE: TAK) has obtained the recommendation of the European Medicines Agency (EMA) Commission for Human Medicines (CHMP) to approve fruquintinib for the treatment of treated adult patients with metastatic colorectal cancer. The European Commission (EC) will take the positive comments of CHMP into account when deciding on marketing licensing fruquintinib for the treatment of metastatic colorectal cancer throughout the European Union, Norway, Liechtenstein, and Iceland. If approved, furoquine
HUTCHMED (China) (LON:HCM) Shareholders Are up 8.2% This Past Week, but Still in the Red Over the Last Five Years
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) rose nearly 7% in the afternoon, and the volume of furoquintinib was rapidly released after launch, and many major products are expected to be approved for major indications
Hewang Pharmaceutical (00013) rose nearly 7% in the afternoon. As of press release, it had risen 6.13% to HK$28.55, with a turnover of HK$94.6406 million.
HUTCHMED Announces Key Managerial LTIP Vesting
HUTCHMED Executives' Incentive Plan Vested
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Ping An Securities: Maintaining the “Recommended” Rating of Hewang Pharmaceutical (00013.HK), 2023 results are in line with expectations
Ping An Securities released a research report stating that considering that the indications for the company's listed products are still expanding, and the pipeline valuation is expected to further improve, maintaining the “recommended” rating of Hehuang Pharmaceutical (00013.HK), the main business revenue for 2024-2026 is estimated to be US$6.71, 8.61, and 1,027 million US dollars, respectively, and net profit of -1.07, 0.2, and 95 million US dollars, respectively, in line with the previous one. The company's total revenue in 2023 was US$838 million (yoy+97%), of which the comprehensive revenue from the oncology/immunology business was US$529 million (yoy+223)
Hutchison Pharmaceutical (0013.HK): 23-year performance is in line with expectations, intensive catalysis in the global innovation pipeline
Matters: On April 8, 2024, Hutchison Pharmaceutical announced its 2023 annual report. The company's total revenue was US$838 million (yoy +97%), of which the comprehensive revenue from the oncology/immunology business was US$529 million (yoy+
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013.HK) is now up nearly 6%. The company announced data at the AACR annual meeting that furoquintinib was released rapidly after listing in the US
Hewang Pharmaceutical (00013.HK) is now up nearly 6%. As of press release, it is up 5.21% to HK$28.25, with a turnover of HK$586.912 million.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
HUTCHMED: 2023 Annual Report
Beijing has brought great benefits to innovative drugs!
In the middle of the night of April 7, the Beijing Municipal Medical Security Administration suddenly issued a “Notice on Public Consultation on the “Certain Measures to Support the High-Quality Development of Innovative Medicines by 9 Departments Including the Beijing Municipal Medical Security Administration (2024) (Draft for Comments)”. The public submission period for this consultation draft is only 3 working days. The first section of the clinical study clearly proposed reducing the overall time required to start a clinical trial to 28 weeks.
Hehuang Pharmaceutical (0013.HK): Major Indications Approved and Expected to Continue to Catalyze Fruquintinib's Entry into the Blue Ocean of Gastric Cancer
Ping An's view: Fruquintinib maintains a leading position in the global third-tier colorectal cancer market, and was rapidly released after marketing in the US. Fruquintinib is a VEGFR inhibitor with excellent target selectivity. It was approved for marketing in China in 2018,2
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
Hutchmed to Present New Data at US Cancer Research Conference
Hutchmed (China) (HKG:0013) will present new and updated data from several studies at the upcoming American Association of Cancer Research Annual Meeting 2024, a Friday filing on the Hong Kong bourse
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other me
No Data